Skip to main content
SpringerLink
Log in
Book cover

Interferone pp 79–91Cite as

Interferon-Antikörper — Phantasie oder Faktum?

  • Chapter

Zusammenfassung

Bereits seit Jahrzehnten werden Proteine therapeutisch beim Menschen eingesetzt. Eine wesentliche Komplikation der Behandlung mit heterologen Proteinen (z. B. Insulin) ist die Bildung von Antikörpern gegen das injizierte Protein [1]. Sind Insulin-Antikörper genügend hochavide und/oder hochtitrig, führen sie zur partiellen oder völligen Unwirksamkeit des injizierten Proteins und zwingen zur Dosiserhöhung oder gar zum Absetzen des jeweiligen Insulins [2, 3]. Bereits der Unterschied von einer Aminosäure zwischen zwei Insulinen (Schweine versus menschliches Insulin) führt zu einer deutlich meßbaren Differenz in der Immunogenität der beiden Stoffe [4]. Die Hoffnung, daß humane Proteine - auf rekombinantem Wege hergestellt - nicht immunogen sind, hat sich leider nicht vollkommen erfüllt. Die Therapie mit humanem rekombinanten Insulin führt in ca. 4% von neu diagnostizierten und nicht vorbehandelten Diabetikern zur Antikörperbildung [4]. Auch die beiden bereits in der Klinik verwandten rekombinanten Wachstumshormon-Präparate der Firmen Lilly und Genetech induzieren nach Angaben der jeweiligen Herstellerfirma Antikörper in 30% bzw. in 2% der chronisch behandelten Patienten. In einem Patienten führten die hochtitrigen Antikörper zu einem Wirkungsverlust des Wachstumshormones [5]. Auch gegen Interleukin 2 und GM-CSF wurden bereits Antikörper in mit diesem Lymphokin (Cetus) behandelten Patienten gefunden [37].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Klaff LJ, Vinik AI, Berelowitz M, Jackson WPU (1978) Circulating antibodies in diabetics treated with conventional and purified insulins. S Afr Med J 54: 149–153

    PubMed  CAS  Google Scholar 

  2. Kahn RC, Rosenthal AS (1979) Immunologic reactions to insulin: Insulin allergy, insulin resistance and the autoimmune insulin syndrome. Diabetes Care 2: 283–295

    Google Scholar 

  3. Walford S, Allison SP, Reeves WG (1982) The effect of insulin antibodies on insulin dose and diabetic control. Diabetologia 22: 106–110

    Article  PubMed  CAS  Google Scholar 

  4. Fineberg SE, Galloway JA, Fineberg NS, Rathebun MJ, Hufferd S (1983) Immunogeni- city of recombinant DNA human insulin. Diabetologia 25: 465–469

    Article  PubMed  CAS  Google Scholar 

  5. National Drug Application. Somatrem, Genetech, Inc 19–107

    Google Scholar 

  6. Vollbracht A, Tremer J, Flekning B, Joester KE, Niethammer D (1981) Interferon-neutralizing antibodies in a patient with fibroblast interferon. Nature 289: 496–497

    Article  Google Scholar 

  7. Mogensen KE, Daubas P, Gresser I, Serini D, Varet B (1981) Patient with circulating antibodies to a-interferon. Lancet 11: 1227–1228

    Article  Google Scholar 

  8. Spiegel JR, Spicehändler JR, Jacobs SL, Oden ME (1986) Low incidence of serum neutralizing factors in patients receiving recombinant alpha-2b interferon. Am J Med 80: 223–228

    Article  PubMed  CAS  Google Scholar 

  9. Itri LM, Campion M, Demin R, Palleroni A, Gutterman JU, Groopman J, Trown PW (1986) Incidence and clinical significance of neutralizing antibodies in patients receiving Roferon A by intramuscular injection. Cancer 59: 668–674

    Article  Google Scholar 

  10. v Wussow P, Jakschies D, Härtung K, Deicher H (1988) Presence of interferon and anti-interferon in patients with systemic lupus erythematosus. Rheumatol Int 8: 225–230

    Article  Google Scholar 

  11. Trown PW, Kramer MJ, Demin RA Jr, Connell EV, Palleroni AV, Quesada J, Gutterman FU (1983) Antibodies to human leukocyte interferons in cancer patients. Lancet 1: 81–84

    Article  PubMed  CAS  Google Scholar 

  12. Panem S, Check IJ, Henriksen D, Vilcek J (1982) Antibodies to a-interferon in a patient with systemic lupus erythematosus. J Immunol 129: 1–3

    PubMed  CAS  Google Scholar 

  13. Hookers JJ, Montsopoulos HM, Geiss SA, Stahl NI, Decker IJ, Notkins AL (1979) Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 301: 5–8

    Article  Google Scholar 

  14. Steis RG, Smith II JW, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenberger C, Longo DL (1988) Resistance to recombinant interferon-alpha 2a in hairy cell leukemia associated with neutralizing anti-IFN-antibodies. N Engl J Med 318: 1409–1413

    Article  PubMed  CAS  Google Scholar 

  15. Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU (1985) Antitumor activity of recombinant-derived interferon-alpha in metastatic renal cell carcinoma. J Clin Oncol 3: 1522–1528

    PubMed  CAS  Google Scholar 

  16. Umeda T, Niijima T (1986) Phase II study of alpha-interferon on renal cell carcinoma. Summary of three collaborative trials. Cancer 58: 1231–1235

    Google Scholar 

  17. Muss HB, Costanzi JJ, Kavit R, et al. (1987) Recombinant alpha-interferon in renal cell carcinoma: A randomized trial of two routes of administration. J Clin Oncol 5: 286–291

    Google Scholar 

  18. de Weck P, Leventhal BG, Brand C, Fisher N (1989) Detection and incidence of neutralizing antibodies to interferon alpha-N-1. J Int Res

    Google Scholar 

  19. v Wussow P, Freund M, Block B, Diedrich H, Poliwoda H, Deicher H (1987) Clinical significance of anti-IFN-alpha antibody titres during interferon therapy. Lancet 11: 635–636

    Article  Google Scholar 

  20. Quesada JR, Itri LM, Gutterman JU (1987) Alpha interferons in hairy cell leukemia: a five year follow up in 100 patients. J Interferon Res

    Google Scholar 

  21. Inglada L, Porres JC, La Banda F, Mora I, Carrcuo V (1987) Anti-IFN-titers during interferon therapy. Lancet 11: 1521

    Article  Google Scholar 

  22. Lassus A, Bergelin I, Paloranta A, Rinne E, Eskelinen A, Säilä K (1987) Efficacy of I FN and planto in the treatment of recurrent genital herpes. Sex Transm Dis 14: 185–190

    Article  PubMed  CAS  Google Scholar 

  23. Protzman WP, Jacobs SL, Minnicozzi M, Oden EM, Kelsey DK (1984) A radioimmunologic technique to scree antibodies to a-2-interferon. J Immunol Meth 75: 317–323

    Article  CAS  Google Scholar 

  24. Hennes U, Jucker W, Fischer EA, Krummacher TH, Palleroni AV, Trown PW, Linder- Ciccolunghi S, Rainisso M (1987) The detection of antibodies to recombinant interferon alpha 2a in human serum. J Biol Stand 15: 231–244

    Article  PubMed  CAS  Google Scholar 

  25. Ingimarsson S, Cantell K, Carlstrom G, Dalton B, Paucker K, Strander H (1981) Immune reactions and long-term therapy with human leukocyte interferon. Acta Med Scand 209: 17–19

    Article  PubMed  CAS  Google Scholar 

  26. Konrad MW, Childs AL, Merigan TC, Borden EC (1987) Assessment of the antigenic response in humans to a recombinant mutant interferon. J Clin Immunol 7: 365–375

    Article  PubMed  CAS  Google Scholar 

  27. Ezekowitz RAB, Dinauer MC, Jaffe HS, Orkin SH, Newburger PE (1988) Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous IFN-y. N Engl J Med 319: 146

    Article  PubMed  CAS  Google Scholar 

  28. Protzman WT, Jacobs SLE, Minnicozzi M, et al. (1984) A radioimmunologic technique to screen for antibodies to alpha-2-interferon. J Immunol Meth 75: 317–323

    Article  CAS  Google Scholar 

  29. Rubinstein S, Familletti PC, Pestka S (1981) Convenient assay for interferons. J Virol 37: 757–460

    Google Scholar 

  30. Hansen MB, Ross C, Berg K (1990) A sensitive antiviral neutralization bioassay for measuring antibodies to interferons. J Immunol Meth 127: 241–248

    Article  CAS  Google Scholar 

  31. Gresser I, Tovey MG, Bandu MT, Maury C, Bronty-Boye D (1976) Role of interferon in the pathogenesis of virus disease in mice as demonstrated by the use of anti-interferon serum. Rapid evolution of EMC virus infection. J exp Med 144: 1305–1315

    Google Scholar 

  32. Gresser I, Tovey MG, Maury C, Bandu MT (1976) Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. J exp Med 144: 1316–1327

    Article  PubMed  CAS  Google Scholar 

  33. v Wussow P, Hartmann F, Freund M, Poliwoda H, Deicher H (1988) Successful treatment of rIFN-a2b-antibody-positive patients with natural IFN-a. Lancet 1: 882–883

    Article  Google Scholar 

  34. Jaffe HS, Chen AB, Kramer S, Sherwin SA (1987) The absence of interferon antibody formation in patients receiving recombinant human interferon-gamma. J Biol Response Modifiers 6: 576–580

    CAS  Google Scholar 

  35. Jacobs SJ, Sullivan LM, Salfi M, Grossberg H, Spiegel RJ, Leikowitz PJ, Oden EM, Kelsey DK, Trauhaft MW (1988) Minimal antigenicity of Intron A in human recipients demonstrated by three analytical methods. Annual Meeting of ISIR, Kyoto, abstract: 1–53

    Google Scholar 

  36. Allegretta M, Atkins MB, Dempsey RA, Bradley EC, Konrad MW, Childs A, Wolfe SN, Mier JW (1986) The development of anti-Interleukin-2 antibodies in patients treated with recombinant human Interleukin-2. J Clin Immunol 6: 481–490

    Article  PubMed  CAS  Google Scholar 

  37. v Wussow P, Freund M, Hartmann F, Dietrich H, Poliwoda H, Deicher H (1988) In: Huhn, Hellriegel, Niederle (eds). Chronic myelocytic leukemia and interferon. Springer Heidelberg Berlin

    Google Scholar 

  38. Kawade Y (1986) Quantitation of neutralization of interferon by antibody. Meth Enzymol 119: 558–573

    Article  PubMed  CAS  Google Scholar 

  39. Oberg K, Alm GV (1989) Development of neutralizing antibodies after treatment with rIFN-a2b in patients with malignant carcinoid tumors. J Interferon Res 9 Suppl. 1: S45–S51

    Google Scholar 

  40. Wolf A. 3. Hannover IFN-Workshop 1988

    Google Scholar 

  41. Krown SE, Real FX, Einzig AI et al. (1985) The interferon system, in: H. Kirschner and H. Schillekens (eds.) Treatment of Kaposi’s Sarcoma and Renal Cell Carcinoma with r Leukocyte A Interferon. Heidelberg Elsevier Science, pp 523–527

    Google Scholar 

Download references

Authors
  1. P. von Wussow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Jakschies
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Med. Klinik III - Onkologie und Hämatologie, Städtisches Krankenhaus, Dhünnberg 60, D-5090, Leverkusen, Deutschland

    Norbert Niederle

  2. Abteilung Immunologie und Transfusionsmedizin, Medizinische Hochschule Hannover, Konstanty-Gutschow-Str. 8, D-3000, Hannover 61, Deutschland

    Peter von Wussow

  3. Zentrum für Innere Medizin und Dermatologie, Medizinische Hochschule Hannover, Konstanty-Gutschow-Str. 8, D-3000, Hannover 61, Deutschland

    Peter von Wussow

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

von Wussow, P., Jakschies, D. (1990). Interferon-Antikörper — Phantasie oder Faktum?. In: Niederle, N., von Wussow, P. (eds) Interferone. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-93383-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93383-7_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-93384-4

  • Online ISBN: 978-3-642-93383-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation